Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Université Paris—sud

Alfact Innovation

University of South Florida

Assistance Publique-Hopitaux De Paris

Université Paris Diderot-Paris 7

Institut National De La Recherche Agronomique (Inra)

Universite Rene Descartes

Université Paris Descartes

Université René Descartes (Paris V)

Université De Paris Xi Paris Sud

Inserm

The Healthy Aging Company

Valerie Courgnaud

Christian Bernard Brechot

Dina Kremsdorf

Colette Porchon

Marion Darnaud

Laure Jamot

Jamila Faivre

Paul Amouyal

Frederique Zindy

Xavier Chenivesse

Jian Wang

Gilles Amouyal

Berthold Henglein

Pierre Sonigo

Paul R Sanberg

Shyam S Mohapatra

Subhra Mohapatra

Joël Dore

Nicolas Moniaux

Alain Pauloin

J Guilherme Tralhao

Marie-Thérèse Simon-Gage-Soufflot

Laurence Christa

Eric Vibert

Jamila Vaivre

Celine Cruciani-Guglielmacci

Christophe Magnan

Fabrizio Andreelli

Pierre Gressens

Elodie Rougier

Céline Cruciani-Guglielmacci

Julie Herve

Jérôme Clerc

A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-&#x3b3; agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-&#x3b2;, and TNF&#x3b1;, which have been associated with SARS-CoV-2 infection.

Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19

The invention concerns a Reg3&#x3b1; polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3&#x3b1; lectin into the gastrointestinal tract (GIT) lumen of hReg3&#x3b1;-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3&#x3b1; exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3&#x3b1;-transgenic mice resist better to DSS-induced colitis after antibiotherapy. Thus, the invention concerns a Reg3&#x3b1; polypeptide for use in the protection of oxygen sensitive gram-positive bacteria, notably the Ruminococcaceae, such as, and/or the Lachnospiraceae, such as; pharmaceutical compositions comprising the polypeptide and their use; and the use of this polypeptide for promoting ex vivo growth of oxygen sensitive gram-positive bacteria. The Reg3&#x3b1; polypeptide may be used for preventing or treating microbiota-related disease and/or disorder, particularly selected from inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders.

Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria

The invention relates to a HIP/PAP protein or to one of the derivatives thereof for use thereof for treating or preventing insulin resistance in non-insulin dependent subjects.

Composition including the HIP/PAP protein or one of the derivatives thereof for treating insulin resistance

This invention concerns a HIP/PAP protein or derivative thereof, for its use in treating or managing cancer and preferentially solid tumors.

HIP/PAP protein and derivatives thereof for use in treating cancer

This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient.

Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure

This invention relates to oligonucleotides encoding HCV E1 peptides, labeled oligonucleotide probes, recombinant DNA molecules comprising HCV E1 nucleotides, plasmid, expression vectors and transformed hosts.

Nucleotide and peptide sequences of an isolate of the hepatitis C virus, diagnostic and therapeutic applications thereof

The invention is directed generally to a DNA sequence coding for human cyclin A and in particular to antibodies, or antisera including such antibodies, which bind to human cyclin A as encoded by the sequence of SEQ ID NO: 1 and which are useful in detecting cellular proliferation. The antibodies of the invention can be polyclonal or monoclonal, and are preferably generated by injection of purified human cyclin A into an animal host. The invention is particularly advantageous because it has been discovered that the gene encoding for human cyclin A is a site for integration of the hepatitis B virus associated with hepatocellular carcinoma, and by detecting human cyclin A through the use of the antibodies of the invention, one can detect and diagnose cell proliferation. Through the use of the present invention, cell proliferation and tumorigenesis can thus be detected at early stages, and such conditions can then be treated or inhibited by the use of anti-sense human cyclin A DNA.

Nucleotide sequence encoding human cyclin A

The invention relates to oligonucleotide sequences (or initiators) derived from the HIV-2 ROD virus genome and from that of the SIV-mac 142 virus, as well as their use in an in vitro method for the diagnosis of the infection of an individual by a HIV-2 type virus.

Oligonucleotide sequences for the amplification of the genome of the

This invention relates to human or murine monoclonal antibodies specific for a peptide sequence of HCV E1, fragments of said monoclonal antibodies, hybridomas producing said monoclonal antibodies, in vitro diagnostic methods for detecting HCV E1-specific antigens in a biological sample, and diagnostic kits for detecting HCV E1-specific antigens in a biological sample.

Nucleotide and peptide sequences of a hepatitis C virus isolate,

This invention relates to purified HCV E1 peptides, immunogenic composition comprising purified HCV E1 peptides, and a diagnostic kit for detecting HCV E1-specific antibodies. The purified HCV E1 peptide has an amino acid selected from the group consisting of SEQ ID NO:3; SEQ ID NO:5; and SEQ ID NO:7.

Process for the detection of cell proliferation by detecting human

Growing community of inventors

Tampa, FL, United States of America

Christian Bernard Brechot